Better Health for All
-20
BD's core business, including medical supplies, devices, laboratory equipment, and diagnostic products, supports patient care in over 90% of US hospitals
1
and aims to improve treatment selection for diseases like cancer, indicating substantial positive health impact. The company reported 1 FDA Class I recall, 23 Class II recalls, and 11 Class III recalls in 2022.
2
In 2025, a voluntary recall of one ChloraPrep product lot occurred due to potential fungal contamination, with severe potential health consequences, though no adverse events were reported at the time.
3
BD's R&D expense of over $1 billion in 2022, representing about 5.3% of its $18.9 billion revenue,
4
is directed towards health improvement. The company demonstrated excellent risk transparency through its voluntary recall and received zero FDA warning letters in both 2022 and 2023.
5
BD holds an enterprise-level ISO certification for its Information Security Management System.
6
For health equity, BD's total contributions in 2022 were $21 million,
7
which is approximately 0.111% of its $18.9 billion revenue.
8
During the COVID-19 pandemic, BD provided nearly $2.5 million in grants and product donations,
9
developed new testing options, and supported patient care in over 90% of US hospitals.
10
Fair Money & Economic Opportunity
0
BDX.US is a medical technology company, and the provided articles do not indicate that it operates as a financial institution or offers consumer lending, deposit, or insurance products. The 'Fair Money & Economic Opportunity' value is designed to assess financial institutions. Consequently, all KPIs related to financial services, such as underserved client share, pricing fairness, exploitative fee exposure, inclusion initiatives, data accessibility, fair lending compliance, wealth building outcomes, financial literacy initiatives, debt burden ratio, geographic inclusion, and product simplicity, are not applicable to BDX.US's core business model. While BD's philanthropic arm contributes to community initiatives, including a rural workforce housing fund that provides low-interest loans, these are not part of BD's own loan book or direct financial services. Furthermore, for profit reinvestment, the articles provide absolute dollar amounts of community investments but do not provide the company's annual pre-tax profit, preventing the calculation of a percentage for this KPI. Therefore, all KPIs are omitted due to lack of direct applicability or specific quantitative data.
Fair Pay & Worker Respect
10
BD's 2024 pay equity assessment confirmed that global female earnings match male counterparts, and in the U.S., female associates earn $1 for every $1 earned by male associates.
1
The 2023 assessment, which covered approximately 70% of its global workforce, showed similar results with U.S. female associates earning 99 cents for every $1 earned by male associates.
2
The CEO-to-median employee pay ratio was 396:1 in Fiscal 2024, a slight decrease from 408:1 in Fiscal 2023.
3
The median employee wage in Fiscal 2024 was $43,763.
4
The company received an overall employee rating of 4.0 out of 5 based on 554 reviews, and a company culture rating of 3.9 out of 5.
5
BD was also named to TIME's 2024 list of the World's Best Companies, partly based on employee satisfaction surveys.
6
There are no substantiated labor-law or human-rights violations reported within the past three years (August 2022 to August 2025).
Fair Trade & Ethical Sourcing
0
BD reported no confirmed instances of forced or child labor in its supply chain as of September 30, 2023.
1
The company conducts a human rights due diligence process that includes risk evaluation, desktop audits, committee review, and on-site audits.
2
This process has identified 68 high-risk suppliers for human rights abuses.
3
BD's "Expectations for Suppliers" document outlines standards for child labor (minimum working age 15, hazardous conditions require 18+) and forced labor, and the company expects suppliers to maintain documentation demonstrating compliance.
4
Honest & Fair Business
10
In December 2024, BD agreed to pay a $175 million civil penalty to the SEC for misleading investors about Alaris infusion pump risks and failing to disclose repair costs.
1
Additionally, in December 2023, the company agreed to an $85 million settlement related to its Alaris infusion pump technology.
2
In December 2022, a subsidiary was fined RMB 154,000 (approximately $21,000 USD) by Shanghai customs for inaccurate declarations of origin.
3
BD received a 100% rating in the 2024 CPA-Zicklin corporate political disclosure and accountability index.
4
Sustainalytics reported an ESG Controversy Level of "None" for the company as of August 2025.
5
The company has stated that no financial restatements were required.
6
BD has a Global Speaking Up Policy and a 24/7 Ethics Helpline available worldwide with translation, explicitly prohibiting retaliation, and outlining investigation procedures tied to the Audit Committee.
7
,
8
The company also has a Global Antibribery & Anticorruption Policy, provides training to all associates, and focuses on compliance within its third-party networks, adhering to laws like the FCPA and UK Bribery Act.
9
,
10
However, there is no conclusive documentation regarding corruption risk assessments, audits of control procedures, or anti-corruption due diligence programs for third parties.
11
Kind to Animals
-40
BD has a Global Animal Welfare Policy, effective October 21, 2024, which promotes ethical and humane treatment of animals and advocates for non-animal alternatives when feasible.
1
The policy commits to the 4Rs of laboratory animal practice (Replace, Reduce, Refine, Retirement/Rehoming)
2
and requires all animal testing by suppliers to be performed under an approved Institutional Animal Care and Use Committee (IACUC) per USDA Guide.
3
BD's Research Animal program undergoes voluntary AAALAC International accreditation every three years,
4
and new programs are expected to pursue this accreditation.
5
However, the company is required to perform preclinical animal studies for FDA approval.
6
Critically, BD has supported animal testing at facilities with histories of failing to adhere to minimal federal guidelines for the treatment of animals in laboratories.
7
No War, No Weapons
0
Becton, Dickinson and Company (BDX.US) was awarded a $100 million contract from the U.S. Department of Defense for its Pyxis™ ES System, an automated medication dispensing platform for military health facilities.
1
The company is subject to the Conflict Minerals Rule and conducted a reasonable country of origin inquiry and due diligence for 2024, filing a Conflict Minerals Report with the SEC.
2
However, BDX was unable to determine the origin of at least a portion of the necessary Conflict Minerals in its products and relies on publicly available information from the RMI without independent verification.
3
In terms of initiatives that mitigate conflict, BD and the BD Foundation committed $7.8 million over three years to support innovative care in community health centers
4
and funded a $500,000 project to improve care quality and equity in U.S. free clinics.
5
The company also engages in disaster relief efforts, including significant cash and product donations for hurricane relief.
6
Planet-Friendly Business
-30
Total Scope 1, 2, and 3 GHG emissions for FY2024 were 6,640,747 tCO2e.
1
Near- and long-term science-based emissions reduction targets were approved by SBTi in April 2024
2
, including a 50% absolute reduction in Scope 1 and 2 GHG emissions by 2030 from a 2019 base year
3
, and a 90% absolute reduction by 2050
4
. Scope 3 GHG emissions are targeted for a 97% reduction per unit of sold product by 2050 from a 2021 base year
5
. In FY2024, 44% of electric power consumption was sourced from renewable sources
6
. Total water use, normalized to Cost of Products Sold, was 487 m³ per $1 million revenue in FY2024
7
. The nonhazardous waste diversion rate from landfill was 77% in FY2024
8
. Sustainability assessments covering 76% of total spend have been completed by over 2,000 suppliers
9
, with BD asking suppliers to disclose carbon emissions data
10
. 34% of suppliers (by emissions covering purchased goods and services and capital goods) have set or committed to set science-based targets
11
. Climate disclosures follow the IFRS S2 Climate-related Disclosures standard, issued in June 2023
12
. The company partnered with BSR to develop four climate scenarios corresponding to warming by 2100, with insights incorporated into its 2030+ goals
13
. 14% of water consumption is sourced from 8 locations within high water risk basins
14
.
Respect for Cultures & Communities
50
BD engaged 1,581 small and diverse-owned supplier partners in the U.S. and Puerto Rico in FY22.
1
These partners include minority-owned businesses.
Safe & Smart Tech
-20
BD has critical issues in vulnerability management, with a high-severity vulnerability (CVE-2024-10476) identified in December 2024 in Diagnostic Solutions Products
1
having a remediation timeline extending into the first half of 2025, which is over 90 days
2
. The company also faces significant regulatory compliance challenges, including a $175 million SEC settlement in Q1 FY2025 for reporting issues related to its Alaris™ infusion pumps prior to 2021
3
, an ongoing FDA consent decree for infusion pumps since 2007
4
, and two FDA Warning Letters in January 2018
5
and November 2024
6
. Authentication security is inconsistent, with some products offering multifactor authentication, PIN, and Active Directory
7
, while others have documented vulnerabilities due to default credentials and missing authentication for critical functions
8
. Encryption implementation is also inconsistent; while specific products like Alaris and Pyxis ES use modern TLS 1.3 and SHA3 for data in transit and at rest
9
, a general statement from November 2025 indicates no additional action to secure data for digital properties
10
, and older Alaris versions had cleartext transmission vulnerabilities
11
. On the positive side, BD holds enterprise-level ISO/IEC 27001:2022 certification (maintained through 2025)
12
, provides SOC2+ reports for multiple products
13
, and has UL CAP certification for participating medical devices
14
. The company provides mandatory quarterly cybersecurity awareness training tailored by role
15
, along with monthly phishing simulations for all users
16
. BD performs comprehensive security testing, including SAST, SCA, fuzz testing, penetration testing, and continuous vulnerability management for critical systems
17
. The company welcomes vulnerability reports from security researchers and partners with them for investigation
18
. BD provides users in certain US states and Europe with rights to know, delete, correct, opt-out of data sale/sharing, and data portability
19
. Furthermore, BD actively participates in numerous industry and government organizations to advance cybersecurity and ethical technology standards
20
. There are no documented data breaches or incidents of unauthorized data use affecting users.
Zero Waste & Sustainable Products
-30
BD reported a 77% manufacturing waste diversion rate from landfill in 2024.
1
The company has established a Design for Sustainability Framework based on the 5Rs (Rethink, Reduce, Reuse, Replace, Recycle)
2
and formed a Sustainable Medical Technology Institute, applying circular design principles to several product categories.
3
BD has implemented numerous waste reduction initiatives, including a circularity pilot with Casella Waste Systems that diverted 40,000 pounds of medical waste,
4
a pilot to recycle blood collection tubes in Denmark,
5
and packaging changes for BD ChloraPrep™ that saved 1.5 million pounds of plastic waste from FY2016 to FY2022.
6
The company has set company-wide targets to reduce nonhazardous waste by 50%, increase landfill diversion to 90%, and increase recycling to 80% by 2030 from a 2019 baseline.
7
However, despite a target to reduce hazardous waste by 50% by 2030,
8
hazardous waste increased by 16% from the 2019 baseline in 2024.
9